GP KFPs / SAQs · musculoskeletal-presentations
Polymyalgia rheumatica and GCA suspicion — KFP-style written assessment
KFP-style staged scenarios on PMR and GCA suspicion: the diagnostic consultation with 2012 criteria and ultrasound, the GCA emergency pathway, the tapering and relapse plan, steroid-harm protection, and the failed-response consultation that unmasks a mimic.
On this page
Study tools
Target exams
RACGP KFPRACGP AKTMRCGP AKT
Prompt
PMR: diagnose it, protect the vision, protect the bones, and know when the label is wrong
KFP 1 (10 marks)
A 71-year-old woman presents with 5 weeks of bilateral shoulder pain, morning stiffness lasting about 75 minutes, and new hip girdle ache. CRP 48 mg/L, ESR 72 mm/h. RF and anti-CCP negative. No headache, no visual symptoms, no jaw or limb claudication. Examination: restricted active shoulder movement bilaterally, no peripheral synovitis, temples normal. [1]
- Score her against the 2012 ACR/EULAR classification criteria and state the performance of the threshold she meets. (3) [1]
- What single bedside investigation would most strengthen the diagnosis, and what finding are you looking for? (2) [3]
- She is offered a rapid-access rheumatology appointment in 5 days. Should you start prednisolone today? Justify against the referral recommendations. (3) [9]
- What GCA screening questions must you document before she leaves? (2) [2]
Model answers
- Morning stiffness >45 minutes (2 points), hip pain (1 point), RF/anti-CCP negative (2 points), no peripheral joint pain (1 point) = 6 points, above the threshold of 4. A score of 4 or more carries 68% sensitivity and 78% specificity against all mimics (88% specificity versus shoulder conditions, 65% versus RA). [1]
- Shoulder ultrasound: bilateral subacromial-subdeltoid bursitis supports PMR (unilateral sens 80%/spec 68%; bilateral sens 66%/spec 89%; bursal thickness over 3 mm separates PMR from rotator cuff tendinopathy — mean 6.9 mm vs 2.3 mm). Adding ultrasound to the criteria raises specificity to 81%. [3]
- No. The international referral recommendations state that where suspected PMR is referred via rapid access, glucocorticoid commencement should be deferred until specialist evaluation — early steroids can blur the diagnostic picture. The exception that would override: any cranial or large-vessel feature, which mandates immediate treatment. [9]
- New or changed headache; scalp or temporal artery tenderness; jaw claudication when chewing; any visual disturbance including transient monocular loss; limb claudication on walking or using arms; fever. Any positive answer converts the plan to immediate 40-60 mg prednisolone and 24-hour specialist review. [2]
References9ShowHide
- [1]Dasgupta B, Cimmino MA, Kremers HM, et al. 2012 Provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative Arthritis Rheum, 2012.PMID 22389040
- [2]Hellmich B, Agueda A, Monti S, et al. 2025 EULAR recommendations for the management of polymyalgia rheumatica and primary large vessel vasculitis Ann Rheum Dis, 2026.PMID 42481270
- [3]Dejaco C, Ramiro S, Duftner C, et al. Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review JAMA, 2016.PMID 27299619
- [4]Terenzi R, Ditto MC, Benucci M, et al. Ultrasound-detected bilateral subacromial-subdeltoid bursitis exceeding 3 mm differentiates polymyalgia rheumatica from rotator cuff tendinopathy Rheumatol Int, 2025.PMID 40892101
- [5]Spiera R, Kissin E, Collinson N, et al. Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper N Engl J Med, 2023.PMID 37792612
- [6]Floris A, Piga M, Chessa E, et al. Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysis Clin Rheumatol, 2022.PMID 34415462
- [7]Buckley L, Guyatt G, Fink HA, et al. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis Arthritis Rheumatol, 2023.PMID 37845798
- [8]González-Gay MA, Vicente-Rabaneda EF, Martínez-López JA, et al. Challenges in the diagnosis of polymyalgia rheumatica and related giant cell arteritis Expert Rev Clin Immunol, 2023.PMID 36896659
- [9]Buttgereit F, Dejaco C, Matteson EL, et al. Recommendations for early referral of individuals with suspected polymyalgia rheumatica: an initiative from the international giant cell arteritis and polymyalgia rheumatica study group Ann Rheum Dis, 2024.PMID 38050004